Using the medical food flavocoxid in managing osteoarthritis

Journal of Pain and Palliative Care Pharmacotherapy

Volumn 25, Issue 1, 2011, Pages 49-54

  Gottlieb, Daniel ^a   Kuritzky, Louis ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Cyclooxygenase (COX); flavocoxid; flavonoid; inflammation; Limbrel; lipoxygenase (LOX); medical food; nonsteroidal anti inflammatory drug (NSAID); osteoarthritis; pain; primary care

Indexed keywords

ARACHIDONIC ACID; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DICLOFENAC EPOLAMINE; FLAVOCOXID; HERBACEOUS AGENT; LIDOCAINE; LIPOXYGENASE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; UNCLASSIFIED DRUG;

AGED; ANALGESIA; ARTHRALGIA; ARTICLE; BLOOD PRESSURE; CASE REPORT; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; KNEE PAIN; OSTEOARTHRITIS; PROTEIN METABOLISM; SIDE EFFECT; TREATMENT RESPONSE; WALKING DIFFICULTY;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARACHIDONATE 5-LIPOXYGENASE; ARACHIDONIC ACID; CATECHIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DRUG COMBINATIONS; HUMANS; OSTEOARTHRITIS, KNEE;

EID: 79953168048     PISSN: 15360288     EISSN: 15360539     Source Type: Journal    
DOI: 10.3109/15360288.2010.548446     Document Type: Article

References (19)

1. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pinkus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-infammatory drugs for osteoarthritis and rheumatoid arthritis.JAMA. 2000;284:1247-1255.
2. Hrachover JB, Mora M. Reporting of 6-month vs 12-month data in a clinical trial ofcelecoxib. JAMA. 2001;286:2399-2400.
3. Wright JM, Perry TL, Bassett KL, Chambers GK. Reporting of 6-month vs 12-month data in a clinical trial of celecoxib. JAMA. 2001;286:2398-2399.
4. Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, et al. National Arthritis Data: estimates of the preva-lence of arthritis and other rheumatic conditions in the United States. Part II, Arthritis Rheum. 2008;58:26-35.
5. Levy RM, Khokhlov A, Kopenkin S, Bart B, Ermolova T, Kan-temirova R, et al. Effcacy and safety offavocoxid, a novel thera-peutic, compared with naproxen: a randomized multicenter con-trolled trial in subjects with osteoarthritis of the knee. Adv Ther. 2010;27:1-12.
6. Walton MS, Schumack GT, McLain DA. Cost analysis of fav-ocoxid compared to naproxen for management of mild to mod-erate OA. Curr Med Res Opin. 2010;26:2253-2261.
7. Singh G. Recent considerations in nonsteroidal anti-infammatory drug gastropathy. Am J Med. 1998;105(1B): 31S-38S. (Pubitemid 28378015)
8. Altavilla D, Squadrito F, Bitto A, Polito F, Burnett BP, Di Stefano V, et al. Flavocoxid, a dual inhibitor of cyclooxyge-nase and 5-lipoxyenase, blunts pro-infammatory phenotype ac-tivation in endotoxin-stimulated macrophages. Br J Pharmacol. 2009;157:1410-1418.
9. Khanapure SP, Garvey DS, Janero DR, Letts LG. Eicosanoids in infammation: biosynthesis, pharmacology, and therapeutic frontiers. Curr Top Med Chem. 2007;7:311-340. (Pubitemid 46358664)
10. Levy RM, Saikovsky R, Shmidt E, Khokhlov A, Burnett BP. Flavocoxid is as effective as naproxen for managing the signs and symptoms of osteoarthritis of the knee in humans; a short-term randomized, double-blind pilot study. Nutr Res. 2009;29:298-304.
11. Antman EM, DeMets D, Loscalzo J. Cyclooxygenase inhibition and cardiovascular risk. Circulation. 2005;112:759-770. (Pubitemid 41099056)
12. Public Health Advisory\FDA Announces Important Changes and Additional Warnings for COX-2 Selective and Non-Selective Non-Steroidal Anti-Infammatory Drugs (NSAIDS). April 7, 2005. Available at: http://www.fda.gov/Drugs/ DrugSafety/PostmarketDrugSafetyInformationforPatientsand-Providers/ucm150314. htm. Accessed December 12, 2010.
13. Hudson N, Balsitis M, Everitt S, Hawkey CJ. Enhanced gas-tric mucosal leukotriene B4 synthesis in patients taking non-steroidalanti-infammatorydrugs. Gut. 1993;34:742-747. (Pubitemid 23185096)
14. Mehrabian M, Allayee H, Wong J, Shi W, Wang XP, Shaposh-nik Z et al. Identifcation of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice. Circ Res. 2002;91:120-126. (Pubitemid 34827222)
15. U.S. Food and Drug Administration. Available at: http://www. fda.gov/Food/GuidanceComplianceRegulatoryInformation/GuidanceDocuments/ MedicalFoods/ucm054048.htm. Ac-cessed December 12, 2010.
16. Morgan SL, Baggott JE, Moreland L, Desmond R, Kendrach A. The safety of favocoxid, a medical food, in the dietary manage-mentofknee osteoarthritis. J Med Food. 2009;12:1143-1148.
17. Limbrel Package Insert, Primus Pharmaceuticals. Available at: http://www.limbrel.com/downloads/limbrel-pi.pdf. Accessed December 12, 2010.
18. Yamada H, Takuma N, Daimon T, Hara Y. Gargling with tea catechin extracts for the prevention of infuenza infection in el-derly nursing home residents; a prospective clinical study. J Al-tern Complement Med. 2006;12:669-672. (Pubitemid 46141019)
19. Burnett BP, Jia Q, Zhao Y, Levy RM. A medicinal extract of Scutelaria baicalensis and Acacia catechu acts as a dual inhibitor of cyclooxygenase and 5-lipoxygenase to reduce infammation. J Med Food. 2007;10:442-451. (Pubitemid 47493490)